(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
@ $2.25
发出时间: 14 Feb 2024 @ 22:30
回报率: -28.00%
上一信号: Feb 14 - 03:04
上一信号:
回报率: 5.14 %
Live Chart Being Loaded With Signals
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety...
Stats | |
---|---|
今日成交量 | 2.48M |
平均成交量 | 1.56M |
市值 | 293.68M |
EPS | $0 ( 2024-05-02 ) |
下一个收益日期 | ( $-0.0500 ) 2024-06-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.71 |
ATR14 | $0.00700 (0.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Green Kevin Dennis | Buy | 21 666 | Common Stock |
2024-03-13 | Green Kevin Dennis | Sell | 21 058 | Common Stock |
2024-03-14 | Green Kevin Dennis | Sell | 21 497 | Common Stock |
2024-03-12 | Green Kevin Dennis | Sell | 21 666 | Restricted Stock Unit |
2024-03-12 | Moore Carol | Buy | 11 666 | Common Stock |
INSIDER POWER |
---|
53.72 |
Last 100 transactions |
Buy: 4 007 373 | Sell: 1 157 608 |
音量 相关性
Cerus Corp 相关性 - 货币/商品
Cerus Corp 财务报表
Annual | 2023 |
营收: | $156.37M |
毛利润: | $84.00M (53.72 %) |
EPS: | $-0.210 |
FY | 2023 |
营收: | $156.37M |
毛利润: | $84.00M (53.72 %) |
EPS: | $-0.210 |
FY | 2022 |
营收: | $162.05M |
毛利润: | $87.09M (53.75 %) |
EPS: | $-0.240 |
FY | 2021 |
营收: | $159.52M |
毛利润: | $96.04M (60.21 %) |
EPS: | $-0.316 |
Financial Reports:
No articles found.
Cerus Corp
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。